Assessment of Fatty Liver Disease using LIVERFASt in South-East Asia (real-world evidence) easlfibronostg on June 26, 2026 Category: Publications Tag: LIVERFASt, MASLD, NAFLD, Screening Post navigation Previous: Previous post: Predictive Value of LIVERFASt, ARFI-FIB-4 to identify chronic Hepatitis B (CHB) — NUH Singapore cohortNext: Next post: LIVERFASt-LFS NIT for Fatty Liver Disease, for Primary Care Provider (PCP) screening
